Changing Pharmaceutical Paradigms
I recently had the pleasure of moderating a discussion of “New Business Paradigms for Pharmaceutical Companies” between John LaMattina and Ronald Breslow at a joint ACS/Société de Chimie Industrielle luncheon in Jersey City, N.J. LaMattina is the former president of Pfizer Global Research & Development and Breslow is a University Professor at Columbia University and a former president of ACS.
The announcement for the luncheon nicely summed up the situation we face: “Many observers believe the traditional pharmaceutical company model is broken. As patents expire, pharmaceutical companies are having an increasingly difficult time filling their product pipelines with new blockbuster drugs. Firms are responding by cutting back on the number of research programs they pursue and the number of researchers that pursue them. They are trying simpler internal structures and more complex external alliances. Results, however, are slow in coming.”
In my comments, I pointed to an unsolicited e-mail I had received the day before the luncheon from Thomson Reuters Pharma on their Pharma Matters Report. The introduction to the report states: “The ‘2011 Pharmaceutical R&D Factbook’ … paints a gloomy picture of the current health of the pharmaceutical industry: R&D expenditures fell in 2010 to a three-year low of $68 billion, while the number of drugs entering phase I, II, and III trials fell by 47, 53, and 55 percent respectively. In addition, only 21 new molecular entities reached the market in 2010, down from 26 in 2009.”
It also states: “This decline in R&D spend is coupled with an increasingly tough regulatory environment, making it more difficult for drugs to progress through pipelines: 55 drugs failed at the phase III stage during 2008-2010, more than double the number of failures during 2005-2007.”
LaMattina’s comments focused on the negative impact of mergers and acquisitions on pharmaceutical R&D (Nature, DOI: 10.1038/nrd3514), calling them “a major factor in the decline in R&D productivity.” He pointed out that the Pharmaceutical Research & Manufacturing Association had 42 members in 1988, of which only 11 exist today as independent companies. While there are more than 11 current members of PhRMA, “the fact is that, due to industry consolidation as well as some companies dropping their pharmaceutical R&D, there is far less competition in this industry than there was a decade ago.”
Two effects of this trend, he said, are that “multiple entries in a compound class—for example, statins—will be less likely to occur” and “mergers result in the net effect of fewer researchers in big pharma R&D.” Multiple entries in a class are important, he said, because the first drug of a class that reaches the market is rarely the best drug. He also argued that multiple drugs in a class foster price competition. As to the second point—that fewer companies means fewer researchers—LaMattina used Pfizer as an example. In absorbing Warner-Lambert, Pharmacia, and Wyeth, he said, numerous research labs were closed and thousands of researchers let go.
Breslow said that the chemistry enterprise faces a “morale” problem. “We used to tell students that, if you take an advanced degree in chemistry, your career will be secure. That’s not true anymore.” Like LaMattina, Breslow took aim at the consolidation of the pharmaceutical industry. “Mergers may make great financial sense, but they are very destructive,” he said. “And not just to the pharmaceutical industry, but to the chemistry community in general because of the damage they do to morale.”
Mergers and acquisitions in the pharmaceutical industry aren’t going away, of course, and LaMattina observed that the biotech industry isn’t immune to the trend. Breslow insisted that the economic strength of the U.S. “is largely based on the strength of our science and technology. Government must continue to recognize that support for science is important.”
While the discussions and the question and answer follow-up were lively and informative, they did not offer much in the way of reassurance for U.S. chemists in the pharmaceutical industry who fear for their futures.
Thanks for reading.